bioRN Espresso: Building Green from the Ground Up: Sustainability in Startup Culture

bioRN Espresso: Building Green from the Ground Up: Sustainability in Startup Culture

Curious how startups are driving sustainability from day one? Join us for an inspiring session as we present two forward-thinking startups who are weaving sustainability into their DNA right from the start.

Discover:

  • Real Strategies: These teams will share their unique approaches to embedding sustainability into every aspect of their operations.
  • Innovative Solutions: Learn how their products are designed to reduce material consumption in the lab, bringing efficiency and eco-friendly practices to the forefront.
  • Marketing with Purpose: We’ll also explore how to integrate sustainability into your marketing strategy—so your values resonate with your audience.

Agenda:

I: LEARNING FROM STARTUPS

Dr. Jannik Jungmann, Phabioc : Starting the Sustainability Journey: PHABIOC’s Approach

Dr. Theresa Schlosser and Dr. Jacqueline De Lora: : “Sustainability at SURFACtoBioTech: Leveraging sustainability principles to drive business development and droplet technology innovation”

 

  • Theresa: defining sustainability and reporting in the context of our startup as an SME, what regulations to be aware of, and towards implementing Sustainable Performance Accounting.
  • Jacqueline: describing how droplet-based experiment partitioning and miniaturization solutions enable labs to implement sustainable practices and standards in their workflows.

II: COMMUNICATION

Dr. Susanne Kuhlendahl, marcommotion: Sustainability in the Life Sciences: Why It matters to your company & How to spread the word

 

register now

Our latest News

discover more
RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Heidelberg, Germany, 19.12.2024 – RHEACELL today received approval from the European Medicines Agency (EMA) for its blinded, multi-centric Phase-3 trial (NCT06489028) evaluating allo-APZ2-CVU in patients with chronic venous ulcers (CVU). The pivotal trial will be conducted at more than 100 sites and is expected to enroll 250 patients, starting enrollment in Europe in Q1 2025. […]

Common cough syrup ingredient shows promise in treating serious lung disease

Common cough syrup ingredient shows promise in treating serious lung disease

EMBL scientists discover that an FDA-approved, over-the-counter cough syrup ingredient has potential to treat fibrotic lung disease. Summary A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions.  Scientists from EMBL Heidelberg were part of a […]

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp